Mycellen Supplements has received a 50 million HUF investment from Obuda Uni Venture Capital to enhance its market presence and product offerings in the health and beauty sector.

Information on the Target

Mycellen Supplements, a prominent local player in the biotechnology-based health and beauty care sector, has secured an investment of 50 million HUF from Obuda Uni Venture Capital (OUVC). The aim of this capital increase is to strengthen the company's market presence, expand its product portfolio, and enhance its communication efforts to promote scientifically supported, preventive health and beauty care.

Mycellen develops premium, innovative dietary supplements and cosmetics that focus on nicotinamide adenine dinucleotide (NAD+). This essential cellular coenzyme plays a vital role in energy production, cellular regeneration, DNA repair, and immune system function. Naturally, the levels of NAD+ decrease with age, which can lead to slower cellular processes, fatigue, and skin aging.

Industry Overview in the Target’s Specific Country

The health and beauty industry in Hungary is experiencing significant growth, driven by increasing consumer demand for scientifically formulated products. With a rising awareness of health and wellness, consumers are leaning tow